CRISPR Therapeutics AG — Director's Dealing 2022

Jun 10, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2022-06-09

Reporting Person: Bolzon Bradley J PhD (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Stock Option (Right to Buy)	$71.70	A	12000	Acquired	2032-06-09	Common Shares (12000)	Direct

Footnotes

F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.